Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: Considerations from a clinical case

Medical Science Monitor

Volumn 9, Issue 4, 2003, Pages

  Torti, Carlo ^a   Moretti, Francesca ^a   Uccelli, Maria Cristina ^a   Tirelli, Valeria ^a   Quiros Roldan, Eugenia ^a   Gargiulo, Franco ^b   Nasta, Paola ^a   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

Author keywords

Drug resistance; HIV; Persistence; Proviral DNA

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CROSS RESISTANCE; DNA DETERMINATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROVIRUS; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; MUTATION; TIME FACTORS; TREATMENT FAILURE;

EID: 0038559640     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Egger M, Hirschel B, Francioli P et al: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ, 1997; 315: 1194-99
2. Kemper CA, Witt MD, Keiser PHman D, and the California Collaborative Treatment Group #575 Team: Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS, 2001; 15: 609-15
3. The Euro Guidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendation for the European setting. AIDS, 2001; 15: 309-320
4. Meynard J, Vray M, Morand-Joubert L et al: Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomised trial. AIDS, 2002; 16: 727-736
5. Garcia F, Vidal C, Plana M: Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis, 2000; 30: 392-394
6. Havlir D, Strain M, Clerici M et al: Productive infection maintains a dynamic steady-state of residual viraemia in HIV-1 infected persons treated with suppressive antiretroviral therapy for 5 years. Antiviral Ther, 2002; 7: 41
7. Aleman S, Soderborg K, Visco-Comandini U et al: Drug resistance at low viremia in HIV-infected patients with antiretroviral combination therapy. AIDS, 2002; 16: 1039-1044
8. Descamps D, Masquelier B, Leport C, and the APROCO Study Group. Detection of resistance mutations in patients receiving a first line protease inhibitor containing regimen with undetectable plasma viral load. Antiviral Ther 2002; 7: 115
9. Opravil M, Hirschel B, Lazzarin A et al: A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis, 2002; 185: 1251-60
10. Pillay D, Mandalia S, Torti C et al: Prognostic significance of HIV-1 resistance tests is enhanced by consideration of multiple test results. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February, 2002 (abstract 593-T)
11. Torti C, Lo Caputo S, Scudeller L et al: Treatment history is an independent factor for short-term virological response of resistance-driven salvage therapy in heavily pretreated patients. Antiviral Ther, 2001; 6(Suppl. 1): 95
12. International AIDS Society-USA Drug Resistance Mutation Group. Drug resistance mutations in HIV-1. IAS-USA Web site. www. iausa.org. Accessed 3rd September, 2002